LUND, Sweden, June 25, 2024 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3 ...
Phase 3 post-hoc analysis indicates less fentanyl and overall illicit opioid use for weekly/monthly buprenorphine depots versus daily standard treatment in a difficult to treat patient population LUND ...
The full CMI on the next page has more details. If you are worried about being given this medicine, speak to your doctor, nurse practitioner or pharmacist. Buvidal contains the active ingredient ...
A "game-changer" jab to treat opioid dependence could ease pressure on health care services, outperforming other standard treatments, a new report involving University of Hertfordshire academics ...
EU Parliament (Photo by artJazz/iStock/Getty Images Plus/Getty Images) The EU’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a new dose of Camurus’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results